Aspira Women's Health Inc embodies values of compassion, innovation, and dedication to improving women's healthcare. With a strong corporate philosophy aimed at empowering women and providing them with accurate diagnostic information, Aspira Women's Health Inc is committed to offering personalized and reliable solutions for early detection of ovarian cancer. Through cutting-edge technologies and a patient-centered approach, the company strives to enhance the lives of women and promote better health outcomes. Aspira Women's Health Inc aims to revolutionize the field of women's health by delivering high-quality diagnostic products and services that prioritize accuracy and patient well-being.

Aspira Women's Health Inc is primarily present in the United States of America.

Aspira Women's Health Inc has achieved significant milestones since its inception. The company has successfully developed and commercialized innovative diagnostic tools and services to improve women's healthcare. Notably, Aspira Women's Health Inc has received FDA clearance for its flagship product, OVA1®, a non-invasive ovarian cancer detection test. Additionally, the company has expanded its test offerings with the launch of Aspira GenetiXSM, a genetic cancer predisposition panel. Aspira Women's Health Inc continues to make strides in advancing early detection and personalized medicine for better women's health outcomes.

Aspira Women's Health Inc is a leading women's health company specializing in the development and commercialization of advanced screening tools for ovarian cancer. Founded in 2008, the company has been at the forefront of revolutionizing early detection and management of gynecologic diseases. Aspira's innovative products, including OVA1 and Overa, provide healthcare professionals with enhanced diagnostic capabilities, allowing for earlier intervention and improved patient outcomes. With a commitment to improving women's health, Aspira Women's Health Inc continues to research, develop, and deliver cutting-edge solutions for gynecologic diseases, making a significant impact in the field of women's healthcare worldwide.

The main competitors of Aspira Women's Health Inc in the market are companies like Myriad Genetics, Inc., Roche Diagnostics, and Hologic, Inc.

Aspira Women's Health Inc is primarily active in the healthcare industry.

Aspira Women's Health Inc. operates as a specialized diagnostic company focused on women's health. The company's business model revolves around offering diagnostic testing services and tools to aid in the early detection and management of gynecologic conditions, particularly ovarian cancer. By leveraging advanced biomarker-based technologies and partnerships with healthcare professionals, Aspira Women's Health aims to provide accurate and timely diagnostic solutions to improve patient outcomes. With a commitment to advancing women's health, the company utilizes innovative approaches and ongoing research to enhance the detection and treatment of gynecologic diseases. Aspira Women's Health Inc. is dedicated to empowering women through accessible and effective diagnostic solutions.

مُعامل القيمة السوقية إلى الأرباح لـ Aspira Women's Health هو ؜-٠٫٦٢.

مُعامِل القيمة إلى المبيعات Aspira Women's Health هو ٠٫٩٣.

نقاط جودة AlleAktien لـ Aspira Women's Health هي 7/10.

المتوقعة Aspira Women's Health الإيرادات هي ١٠٫٥٨ مليون. USD.

صافي الربح المتوقعة Aspira Women's Health هو ؜-١٥٫٨٤ مليون. USD.

Aspira Women's Health Inc. is an innovative company in the healthcare industry that focuses on the development and marketing of diagnostic and therapeutic solutions for women. The company was founded in 2017 through the merger of Aspira Labs and Vermillion and has since taken a leading role in the industry. Aspira Women's Health offers a variety of products and services aimed at improving women's health and providing better diagnostic options. One of the company's main areas is identifying risk factors for early detection of ovarian cancer. For this purpose, the company has developed the OVA1 test, which measures a combination of five marker proteins to help identify the risk of ovarian cancer. The goal is to enable early detection of ovarian cancer to improve treatment and cure chances. Other products from Aspira Women's Health include the Aspira Sampling Brush Kit, which allows patients to collect cervical cells through a simple and painless vaginal swab. The kit enables quick and reliable analysis of cell samples and thus the prevention and treatment of cervical cancer. Another important area of the company is medical research and development. Aspira Women's Health continuously invests in innovative technologies and R&D programs to explore and develop new diagnostic and therapeutic options. As a healthcare company, Aspira Women's Health has a broad network of partners and customers, including doctors, hospitals, research institutions, and pharmaceutical manufacturers. The company builds on these relationships to market its solutions effectively and expand its business activities. Aspira Women's Health's business model is designed for sustainable growth and long-term success. The company has developed clear financial goals and strategies that consider both operational and clinical engagement. The company works to continuously improve and expand its services and products to meet the needs of its customers and partners. In summary, Aspira Women's Health is a leading company in the field of women's health, offering innovative solutions for the prevention, detection, and treatment of cancer and other diseases. With a strong market position, a wide portfolio of products and services, and continuous investment in R&D, the company is working hard to improve the lives of women worldwide.

يوزع Aspira Women's Health أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Aspira Women's Health في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـAspira Women's Health هو US04537Y1091.

رمز WKN لـ Aspira Women's Health هو A2P6V3.

الرمز المُختصر لـ Aspira Women's Health هو AWH.

خلال آخر 12 شهراً، دفعت Aspira Women's Health توزيعات أرباح بقيمة ٠٫٥٢ USD . وهذا يعادل عائد توزيعات أرباح يقارب ٤٨٫٦١ %. ومن المتوقع أن تدفع Aspira Women's Health خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ Aspira Women's Health هي ٤٨٫٦١ %.

Aspira Women's Health يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر يوليو, أكتوبر, أبريل, يوليو.

Aspira Women's Health دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Aspira Women's Health يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة ٠٫٢٦ USD من Aspira Women's Health المُعلن عنها في ٣٠‏/٦‏/٢٠١٦، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ١٧‏/٦‏/٢٠١٦.

تم توزيع آخر دفعة من الأرباح بتاريخ ٣٠‏/٦‏/٢٠١٦.

في العام 2023، وزعت Aspira Women's Health 0 USD كأرباح أسهم.

يتم توزيع أرباح Aspira Women's Health بالعملة USD.